BackCytek BioSciences Overview
Cytek BioSciences Inc

Cytek BioSciences Target Price

See Cytek BioSciences's analyst price targets ($5.1) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$4.67

Average Target Price

$5.088.9% upside

3 analysts in the last 4 months

High: $5.5 | Low: $4.75

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-07Morgan Stanley$57.1% upsideOpen
2026-05-13Stephens$4.751.7% upsideOpen
2026-05-12Morgan Stanley$5.517.8% upsideOpen
2025-12-01Morgan Stanley$628.5% upsideOpen
2025-03-04Piper Sandler$871.3% upsideOpen
2025-02-02Goldman SachsMatthew Sykes$5.2512.4% upsideOpen
2024-05-13Piper SandlerDave Westenberg$8.582% upsideOpen
2022-08-17Piper SandlerDavid Westenberg$16242.6% upsideOpen
2022-05-15Piper SandlerDavid Westenberg$12157% upsideOpen

Cytek BioSciences (CTKB) FAQ

Cytek BioSciences posts a target price of $5.1. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $5.1 for CTKB means covering analysts, on average, see the stock 8.9% upside of $4.67 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for CTKB's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Cytek BioSciences's other metric pages and overview cover the third.

Judging Cytek BioSciences against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $5.1 here, then scan peer and history charts to see if the gap is persistent.